Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mesothelin: a new target for immunotherapy.

Raffit Hassan1, Tapan Bera, Ira Pastan

  • 1Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, Maryland, USA. hassanr@mail.nih.gov

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|June 26, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic Significance of Inflammatory, Cellular, and Tumor-Specific Biomarkers in Patients With Pleural and Peritoneal Mesothelioma.

Clinical lung cancer·2026
Same author

USP40 protects podocytes by deubiquitylating integrin β1.

Biochemical and biophysical research communications·2026
Same author

Corrigendum to 'Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact' [Journal of Thoracic Oncology Volume 21 Issue 1 (2026) 41-76].

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

Recent advances in structural investigations of cancer antigen mesothelin and its interactions with therapeutic antibodies.

Antibody therapeutics·2026
Same author

RO4, a high-affinity humanized antibody against the juxtamembrane region of mesothelin for targeted cancer therapy.

Antibody therapeutics·2026
Same author

Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same journal

Presenting features and outcomes to standard systemic therapies in patients with MTAP-deleted advanced non-small cell lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Claudin 18.2 Targeting: A Pan-Cancer Perspective.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
See all related articles

Mesothelin, a protein overexpressed in cancers like mesothelioma, is a promising target for new cancer therapies. Research explores its potential in immunotoxins and cancer vaccines for improved treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Mesothelin is a cell surface protein found on normal mesothelial cells.
  • It is significantly overexpressed in various cancers, including mesothelioma, ovarian, and pancreatic adenocarcinomas.
  • Its precise biological function remains largely unknown.

Purpose of the Study:

  • To investigate mesothelin as a therapeutic target for cancer.
  • To explore the potential of mesothelin-based immunotherapies, including immunotoxins and cancer vaccines.
  • To evaluate a soluble mesothelin variant as a potential tumor marker.

Main Methods:

  • Review of existing literature on mesothelin expression and function.
  • Analysis of the development and clinical evaluation of anti-mesothelin immunotoxin SS1(dsFv)PE38.

Related Experiment Videos

  • Discussion of evidence supporting mesothelin's immunogenicity for vaccine development.

    • Main Results:

    • Mesothelin's limited expression in normal tissues and high tumor expression make it an attractive target for tumor-specific therapy.
    • The anti-mesothelin immunotoxin SS1(dsFv)PE38 is in clinical trials for mesothelin-expressing tumors.
    • Mesothelin shows potential as a target for therapeutic cancer vaccines due to its immunogenic properties.

    Conclusions:

    • Mesothelin represents a promising target for novel cancer therapies, including immunotoxins and vaccines.
    • Further research into mesothelin's role in cancer could lead to improved diagnostic and therapeutic strategies.
    • A soluble mesothelin variant may serve as a valuable biomarker for malignant mesotheliomas.